Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has encountered...

Descripción completa

Detalles Bibliográficos
Autores principales: Mardi, Amirhossein, Shirokova, Anastasia V., Mohammed, Rebar N., Keshavarz, Ali, Zekiy, Angelina O., Thangavelu, Lakshmi, Mohamad, Talar Ahmad Merza, Marofi, Faroogh, Shomali, Navid, Zamani, Amir, Akbari, Morteza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052538/
https://www.ncbi.nlm.nih.gov/pubmed/35488303
http://dx.doi.org/10.1186/s12935-022-02585-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052538/
https://www.ncbi.nlm.nih.gov/pubmed/35488303
http://dx.doi.org/10.1186/s12935-022-02585-z

Ejemplares similares